Estudos sobre a fauna de Sarcophagidae (Diptera) de Belo Horizonte - Minas Gerais. I- Levantamento taxonômico e Sinantrópico

Com o objetivo de se conhecer a fauna de Sarcophagidae da região de Belo Horizonte, Minas Gerais, e se obter dados sobre seu comportamento, foram realizadas capturas sistemáticas em três áreas ecologicamente distintas, pelo período de um ano (maio de 1980 a abril de 1981). Para as capturas, foram utilizadas dois tipos de armadilhas apropriadas e cinco tipos de iscas; peixe cru, carcaça de camundongo, v´sceras de galinha, banana amassada com rapadura e fezes humanas. Foi capturado um total de 10.097 espécimens, dos quais foram estudados 9.582 exemplares, representados por 25 espécies. O índice de sinantropia foi determinado segundo a metodologia de Nuorteva (1963). Foram obtidos índices variáveis de sinantropia para as 25 espécies analisadas, sendo as mais sinantrópicas Parasarcophaga ruficornis (IS = + 94,7) e Bercaea haemorrhoidalis (IS = + 84,3), e as mais assinantrópicas Euboettcheria florencioi (IS = - 98,8) e Oxysarcodexia augusta (IS = - 96,9).

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Analisi espacial del canvi climàtic al continent europeu. Incerteses i exposicions principals

El canvi climàtic del segle XXI és una realitat, hi ha moltes evidències científiques que indiquen que l’escalfament del sistema climàtic és inequívoc. Malgrat això, també hi ha moltes incerteses respecte els impactes que pot comportar aquest canvi climàtic global. L’objectiu d’aquest projecte és estudiar la possible evolució futura de tres variables climàtiques, que són el rang de la temperatura diürna a prop de la superfície (DTR), la temperatura mitjana a prop de la superfície (MT) i la precipitació mensual (PL_mes) i valorar l’exposició que poden experimentar diferents cobertes del sòl i diferents regions biogeogràfiques del continent europeu davant d’aquests possibles patrons de canvi. Per això s’han utilitzat Models Climàtics Globals que fan projeccions de variables climàtiques que permeten preveure el possible clima futur. Mitjançant l’aplicatiu informàtic Tetyn s’han extret els paràmetres climàtics dels conjunts de dades del Tyndall Centre for Climate Change Research, del futur (TYN SC) i del passat (CRU TS). Les variables obtingudes s’han processat amb eines de sistemes d’informació geogràfica (SIG) per obtenir els patrons de canvi de les variables a cada coberta del sòl. Els resultats obtinguts mostren que hi ha una gran variabilitat, que augmenta amb el temps, entre els diferents models climàtics i escenaris considerats, que posa de manifest la incertesa associada a la modelització climàtica, a la generació d’escenaris d’emissions i a la naturalesa dinàmica i no determinista del sistema climàtic. Però en general, mostren que les glaceres seran una de les cobertes més exposades al canvi climàtic, i la mediterrània, una de les regions més vulnerables

Y-90 Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced Stage Follicular Non Hodgkin's Lymphoma Updated Results After a Median Follow up of 662 Months From the International, Randomized, Phase III First Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

PURPOSE: We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission. PATIENTS AND METHODS: Patients with CD20(+) stage III or IV follicular lymphoma, who achieved a complete response (CR)/unconfirmed CR (CRu) or partial response (PR) after first-line induction treatment, were randomly assigned to receive (90)Y-ibritumomab tiuxetan (rituximab 250 mg/m(2) on day -7 and day 0 followed on day 0 by (90)Y-ibritumomab tiuxetan 14.8 MBq/kg; maximum of 1,184 MBq) or no further treatment (control). The primary end point was progression-free survival (PFS), which was calculated from the time of random assignment. RESULTS: A total of 414 patients (consolidation, n = 208; control, n = 206) were enrolled at 77 centers. (90)Y-ibritumomab tiuxetan consolidation significantly prolonged median PFS (after a median observation time of 3.5 years) in all patients (36.5 v 13.3 months in control arm; hazard ratio [HR] = 0.465; P &lt; .0001) and regardless of whether patients achieved PR (29.3 v 6.2 months in control arm; HR = 0.304; P &lt; .0001) or CR/CRu (53.9 v 29.5 months in control arm; HR = 0.613; P = .0154) after induction treatment. Median PFS with consolidation was prolonged in all Follicular Lymphoma International Prognostic Index risk subgroups. After (90)Y-ibritumomab tiuxetan consolidation, 77% of patients in PR after induction converted to CR/CRu, resulting in a final CR rate of 87%. The most common toxicity with (90)Y-ibritumomab tiuxetan was hematologic, and grade 3 or 4 infections occurred in 8% of patients. CONCLUSION: Consolidation of first remission with (90)Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

We present the long-term results of 18 chemotherapy relapsed indolent (N = 12) or transformed (N = 6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody combined with (131)I-tositumomab once as dosimetric and once as therapeutic activity delivering 75 or 65 cGy whole-body radiation dose to patients with normal or reduced platelet counts, respectively. Two patients were not treated due to disease progression during dosimetry. The overall response rate was 81% in the 16 patients treated, including 50% CR/CRu and 31% PR. Median progression free survival of the 16 patients was 22.5 months. Median overall survival has not been reached after a median observation of 48 months. Median PFS of complete responders (CR/CRu) has not been reached and will be greater than 51 months. Short-term side effects were mainly haematological and transient. Among the relevant long-term side effects, one patient previously treated with CHOP chemotherapy died from secondary myelodysplasia. Four patients developed HAMA. In conclusion, (131)I-tositumomab RIT demonstrated durable responses especially in those patients who achieved a complete response. Six of eight CR/CRu are ongoing after 46-70 months.

Desenvolvimento pós-embrionário de Pattonella intermutans (Thomson) (Diptera: Sarcophagidae) em diferentes dietas

A proposta deste estudo foi de avaliar o desenvolvimento pós-embrionário de Pattonella intermutans (Thomson, 1869) em dietas artificiais preparadas com agar-agar. Dieta D1: leite em pó integral + fermento biológico; Dieta D2: leite em pó integral + fermento biológico + caseína; Dieta D3: leite em pó integral + ovo cru; Dieta D4: carne bovina moída (dieta controle). A carne bovina moída foi a dieta mais eficiente (peso larval de 195,63 mg e viabilidade de neolarva a adulto de 86,5%), quando comparada com as dietas artificiais. Os seguintes resultados foram obtidos para o grupo experimental: Dieta D3: 180,15 mg e 63,5%; Dieta D2: 141,07 mg e 61% e na Dieta D1: 147,98 mg e 51,5%.

Contagem de Staphylococcus coagulase positivo e Escherichia coli nas amostras de queijo fresco da ilha do Fogo comercializado no mercado municipal da cidade da Praia

O presente trabalho monográfico elaborado como parte dos requisitos para obtenção do grau de licenciatura em Análises Clínicas e Saúde Pública, teve como objectivo proceder à contagem de Staphylococcus coagulase positivo e Escherichia coli nas amostras de queijo fresco da ilha do Fogo comercializado no mercado municipal da cidade da Praia. O queijo é um derivado do leite muito apreciado devido ao seu valor nutritivo como também pelo seu sabor, que consegue atender aos mais diferentes paladares. Mas, muitas vezes as condições de processamento, armazenamento e comercialização poderão comprometer as suas características organolépticas, ou torná-lo impróprio para o consumo humano através de contaminação por microrganismos causadores das toxinfecções alimentares ( CORBIA et al., 2000; MELO, 2009 ) . A presença desses microrganismos no queijo poderá ter como fonte de contaminação a utilização do leite cru, utensílios contaminados utilizados durante o processo de fabrico, condições higiénico-sanitária precárias. Para a avaliação da qualidade microbiológica do queijo fresco artesanal comercializado no mercado da cidade da Praia, foram analisadas 40 amostras de queijos provenientes da ilha do Fogo que são comercializados neste estabelecimento. A técnica utilizada para a contagem das bactérias Staphylococcus coagulase positiva foi a de sementeira a superfície e para Escherichia coli fez-se pelo método de incorporação. Dos resultados obtidos para a contagem de Staphylococcus coagulase positiva 87,5% das amostras analisadas estavam contaminadas e para Escherichia coli 82,5% das amostras estavam também contaminadas, o que de acordo com a Resolução - RDC nº 12, de 2 de Janeiro de 2001 da ANVISA, estão fora do limite estabelecido, e estando assim insatisfatórias para o consumo humano. Concluiu-se que os queijos frescos da ilha do Fogo comercializados no mercado municipal da cidade da Praia não são de boa qualidade para o consumo humano. Os produtores do queijo e as vendedeiras precisam de formações sobre as boas práticas de higiene e de fabrico a fim de obtermos um produto de qualidade e isento de microrganismos que são prejudiciais à saúde do consumidor.

Contagem de Staphylococcus coagulase positivo e Escherichia coli nas amostras de queijo fresco da ilha do Fogo comercializado no mercado municipal da cidade da Praia

O presente trabalho monográfico elaborado como parte dos requisitos para obtenção do grau de licenciatura em Análises Clínicas e Saúde Pública, teve como objectivo proceder à contagem de Staphylococcus coagulase positivo e Escherichia coli nas amostras de queijo fresco da ilha do Fogo comercializado no mercado municipal da cidade da Praia. O queijo é um derivado do leite muito apreciado devido ao seu valor nutritivo como também pelo seu sabor, que consegue atender aos mais diferentes paladares. Mas, muitas vezes as condições de processamento, armazenamento e comercialização poderão comprometer as suas características organolépticas, ou torná-lo impróprio para o consumo humano através de contaminação por microrganismos causadores das toxinfecções alimentares (CORBIA et al., 2000; MELO, 2009). A presença desses microrganismos no queijo poderá ter como fonte de contaminação a utilização do leite cru, utensílios contaminados utilizados durante o processo de fabrico, condições higiénico-sanitária precárias. Para a avaliação da qualidade microbiológica do queijo fresco artesanal comercializado no mercado da cidade da Praia, foram analisadas 40 amostras de queijos provenientes da ilha do Fogo que são comercializados neste estabelecimento. A técnica utilizada para a contagem das bactérias Staphylococcus coagulase positiva foi a de sementeira a superfície e para Escherichia coli fez-se pelo método de incorporação. Dos resultados obtidos para a contagem de Staphylococcus coagulase positiva 87,5% das amostras analisadas estavam contaminadas e para Escherichia coli 82,5% das amostras estavam também contaminadas, o que de acordo com a Resolução - RDC no 12, de 2 de Janeiro de 2001 da ANVISA, estão fora do limite estabelecido, e estando assim insatisfatórias para o consumo humano. Concluiu-se que os queijos frescos da ilha do Fogo comercializados no mercado municipal da cidade da Praia não são de boa qualidade para o consumo humano. Os produtores do queijo e as vendedeiras precisam de formações sobre as boas práticas de higiene e de fabrico a fim de obtermos um produto de qualidade e isento de microrganismos que são prejudiciais à saúde do consumidor.

Partie d'une « Bible historiée toute figurée ».

Miniatures italiennes à chaque page. — Cet exemplaire n'est pas, comme on l'a cru, celui qui avait appartenu à la reine Jeanne d'Évreux, femme de Charles le Bel, puis au roi Charles V.

Evolução quaternária, distribuição de partículas nos solos e ambientes de sedimentação em manguezais do estado de São Paulo

A distribuição de partículas em solos ou sedimentos das planícies litorâneas auxilia no entendimento dos processos de sedimentação em estuários, servindo com importante atributo para aplicações em estudos de reconstrução paleoambiental, ciclos geoquímicos e poluição ambiental, como contaminação por metais pesados e derrames de petróleo, que, devido à ação antrópica, são relativamente comuns nesses ambientes. Com o objetivo de caracterizar os ambientes de sedimentação de acordo com a granulometria e com o processo de evolução quaternária ao longo do litoral do Estado de São Paulo, foram estudados solos de 14 manguezais. As análises granulométricas foram realizadas nas camadas de 0-20 e 60-80 cm de profundidade, determinando as frações argila, silte, areia total e cinco frações da areia. Realizaram-se datações 14C por cintilação líquida, espectrometria de massa acoplada a acelerador de partículas na fração humina da matéria orgânica e por termoluminescência em grãos de quartzo, para amostras de diferentes camadas dos manguezais amostrados. Os resultados de granulometria foram tratados de acordo com os parâmetros estatísticos de Folk & Ward. Os solos dos manguezais do Estado de São Paulo têm idade holocênica oscilando entre 410 e 3.700 anos AP, até a profundidade de 80 cm. Em alguns casos este substrato holocênico encontra-se sobreposto à camada arenosa pleistocênica, como foi identificado em SG1 (65-77 cm = 11.000 anos e 90-95 cm = 24.700 anos), PM (72-79 cm = 60.000 anos) e em RF, cuja camada a 40-50 cm apresentou idade de 12.200 anos. Os manguezais apresentam solos de diferentes texturas, variando de arenosa a argilosa. Os solos de constituição arenosa foram identificados na Ilha do Cardoso, na planície do Rio Guaratuba e ao longo do litoral norte, cujos manguezais foram estabelecidos sobre os sedimentos retrabalhados de antigos cordões arenosos e localizados às margens dos rios que drenam essas planícies litorâneas (SG1, SG2, GUA e RE). Esses solos ocorrem também nas proximidades da desembocadura dos rios, onde há maior influência da ação de ondas (RF). Os manguezais cujo substrato são constituídos, predominantemente, de partículas finas (silte e argila) estão localizados nos compartimentos mais protegidos do litoral, como o Canal do Cananéia (PM e BAG), Mar Pequeno (IGUA) e dentro do estuário de Santos, na Baixada Santista (ITA, IRI, COS e CRU). O período de maré estacionada, que decorre da alternância dos ciclos de enchente e vazante desta, favoreceria a sedimentação de partículas da fração silte, explicando a ocorrência de alto teor de silte na superfície dos solos de manguezais de PM e BAG e ao longo das camadas estudadas de IGUA e ITA.

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after (90) Y-ibritumomab-tiuxetan.

Radioimmunotherapies with Zevalin® (RIT-Z) showed encouraging results in patients with relapsed/refractory follicular lymphoma (FL), leading frequently to failure-free intervals longer than those achieved by the last previous therapy. We compared time-to-event variables obtained before and after RIT-Z in patients with relapsed FL, previously exposed to rituximab. All patients with relapsed non-transformed, non-refractory, non-rituximab-naïve FL who have been treated with RIT-Z in two different centres in Europe were included. Staging and response were assessed by contrast-enhanced CT in all patients; PET/CT was performed according to local availability. Event-free survival (EFS) and time to next treatment (TTNT) following the last previous therapy and after RIT-Z were compared. Pre-therapy characteristics were tested in univariate analyses for prediction of outcomes. A description of the patterns of relapse was also provided. Among 70 patients treated, only 16 fulfilled the inclusion criteria. They were treated with a median of 3 prior lines of chemo-immunotherapies, including a median of 2 rituximab-containing regimens; 6 patients had undergone myeloablative chemotherapy with autologous stem cell rescue (ASCT). Overall response rates were 10 (62%) CR/CRu, 3 (19%) PR and 3 (19%) PD; response rates were similar in patients with prior ASCT. After RIT-Z only few patients obtained EFS and TTNT longer than after the last previous therapy. All four patients receiving rituximab maintenance were without progression 12 months after RIT-Z. Relapses occurred in both previously and newly involved sites; a significant association was found between the number of pathologic sites involved prior to RIT-Z and subsequent TTNT. Despite the excellent response rate, the duration of response was shorter than the previous one confirming the known trend of relapses to occur earlier after subsequent treatments. Rituximab maintenance after RIT-Z showed encouraging results in terms of prolonging EFS, warranting further studies. Copyright © 2010 John Wiley &amp; Sons, Ltd.

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial.

PURPOSE Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. PATIENTS AND METHODS Patients with CD20(+) stage III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.8 MBq/kg day 0; maximum 1,184 MBq) or no further treatment (control). Primary end point was progression-free survival (PFS) from date of random assignment. Results For 409 patients available for analysis ((90)Y-ibritumomab, n = 207; control, n = 202), estimated 8-year overall PFS was 41% with (90)Y-ibritumomab versus 22% for control (hazard ratio [HR], 0.47; P < .001). For patients in CR/CRu after induction, 8-year PFS with (90)Y-ibritumomab was 48% versus 32% for control (HR, 0.61; P = .008), and for PR patients, it was 33% versus 10% (HR, 0.38; P < .001). For (90)Y-ibritumomab consolidation, median PFS was 4.1 years (v 1.1 years for control; P < .001). Median time to next treatment (TTNT) was 8.1 years for (90)Y-ibritumomab versus 3.0 years for control (P < .001) with approximately 80% response rates to second-line therapy in either arm, including autologous stem-cell transplantation. No unexpected toxicities emerged during long-term follow-up. Estimated between-group 8-year overall survival rates were similar. Annualized incidence rate of myelodysplastic syndrome/acute myeloblastic leukemia was 0.50% versus 0.07% in (90)Y-ibritumomab and control groups, respectively (P = .042). CONCLUSION (90)Y-ibritumomab consolidation after achieving PR or CR/CRu to induction confers 3-year benefit in median PFS with durable 19% PFS advantage at 8 years and improves TTNT by 5.1 years for patients with advanced FL.

Efeito da eliminação genética das lipoxigenases das sementes sobre as características agronômicas da soja

A eliminação genética das enzimas lipoxigenases (Lox 1, Lox 2 e Lox 3) é uma das maneiras de se contornar os problemas associados ao sabor indesejável de "feijão cru" das sementes da soja. Visando elucidar a influência dessa eliminação genética nas características agronômicas da planta de soja e nos componentes de produção, a variedade comercial de soja FT-Cristalina RCH e suas linhagens, obtidas por retrocruzamentos, sem as três lipoxigenases nas sementes (linhagens triplo-nulas) e com as três lipoxigenases (triplo-positivas), foram avaliadas em três épocas de semeadura. A variedade comercial foi mais homogênea que as linhagens com ou sem lipoxigenases, indicando presença de quantidade significativa de genes dos progenitores não-recorrentes nas linhagens, principalmente nas sem lipoxigenases. A semeadura em diferentes épocas evidenciou variação entre os materiais genéticos (variedade comercial, linhagens com ou sem lipoxigenase nas sementes), tanto nas características da planta quanto nos componentes de produção de grãos. A eliminação genética das lipoxigenases das sementes não afetou negativamente as características agronômicas da variedade FT-Cristalina RCH.